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Clinical pain is a serious public health issue. Treatment of pain-related suffering requires knowl-
edge of howpain signals are initially interpreted and subsequently transmitted and perpetuated.
This review article is one of three reviews in this issue of Neuron that address our understanding
of the pain process and possible solutions to the problem from both cellular- and systems-level
viewpoints.
In order to deal effectively with danger, it is imperative to know about it. This is what nociceptors do—
these primary sensory neurons are specialized to detect intense stimuli and represent, therefore, the
first line of defense against any potentially threatening or damaging environmental inputs. By sensing
noxious stimuli and contributing to the necessary reactions to avoid them—rapid withdrawal and the
experience of an intensely unpleasant or painful sensation, nociceptors are essential for the main-
tenance of the body’s integrity. Although nociceptive pain is clearly an adaptive alarm system, per-
sistent pain is maladaptive, essentially an ongoing false alarm. Here, we highlight the genesis of
nociceptors during development and the intrinsic properties of nociceptors that enable them to
transduce, conduct, and transmit nociceptive information and also discuss how their phenotypic
plasticity contributes to clinical pain.As a result of physiological experiments he conducted at
the dawn of the 20th century, Charles Sherrington con-
cluded, ‘‘There is considerable evidence that the skin is
provided with a set of nerve endings whose specific office
it is to be amenable to stimuli that do the skin injury, stimuli
that in continuing to act would injure it still further’’ (Sher-
rington, 1903). He further stated that since ‘‘harmfulness is
the characteristic of the stimuli by which [the nerve end-
ings] are provocable.for physiological reference there-
fore they are preferably termed nocicipient’’ (Sherrington,
1903). A few years later Sherrington expanded his defini-
tion of a noxious stimulus as one with an intensity and
quality sufficient to trigger reflex withdrawal, autonomic
responses, and pain, collectively constituting what he
called the nociceptive reaction. He also redefined the neu-
ral apparatus responsible for detecting a noxious stimulus
as nociceptive nerves or nociceptors (Sherrington, 1906).
Implicit in this new term, coined 100 years ago, was that
pain is a specific sensation with its own sensory machin-
ery. This view was something that Descartes and von
Frey had also argued in favor of, although in rather differ-
ent ways. Sherrington’s notion was directly counter to
then widely held theories that pain resulted from a central
summation in response to excessive sensory stimulation
or that all nerve endings are similar and that certain pat-
terns of activity produced by intense stimulation evoke
pain. Fundamentally, this divergence reflected the com-
peting specificity and pattern theories of pain that charac-terized much of 19th and early 20th century pain sensory
biology. The debate reached a climax in the 1960s and
70s with Ed Perl arguing vigorously that pain is mediated
by specialized high-threshold nociceptor sensory neurons
(Bessou and Perl, 1969), and Pat Wall and Ron Melzack
emphatically emphasizing central processing as generat-
ing pain (Melzack and Wall, 1965). It is now clear that this
clash of the sensory titans was quite artificial. It is not an
either/or situation; nociceptors are indeed the peripheral
path to nociceptive pain, and altered central processing
does contribute to pain hypersensitivity in patients. We
can, however, now quietly relegate the view that sensory
specificity is encoded by activity in nonspecialized pri-
mary sensory neurons to the garbage can of history and
instead loudly celebrate the first century of the nociceptor,
a specialized noxious stimulus detector. We also increas-
ingly recognize that the nociceptor is highly modifiable in
response to injury of its axon and on exposure to inflam-
mation and that this plasticity is integral to its pain-gener-
ating functions and may reflect, moreover, a recapitulation
of the signaling that determines its differentiation during
development.
In interacting with the environment, living organisms
have to recognize and react to harmful stimuli to avoid
them. To do this, nociceptors have a high threshold and
normally respond, as Sherrington clearly recognized,
only to stimuli of sufficient energy to potentially or actually
damage tissue. Some nociceptors are thinly myelinatedNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 353
Neuron
ReviewFigure 1. The Nociceptor
(A) The operational components of the noci-
ceptor include a peripheral terminal that inner-
vates target tissue and transduces noxious
stimuli, an axon that conducts action potentials
from the periphery to the central nervous sys-
tem, a cell body in the dorsal root ganglion,
and a central terminal where information is
transferred to second order neurons at central
synapses.
(B) Transduction is mediated by high-threshold
transducer ion channels which depolarize the
peripheral terminal activating voltage-depen-
dent sodium channels. Transmission occurs
in response to calcium influx at the central ter-
minal releasing glutamate as well as multiple
synaptic modulators and signaling molecules
and is subject to both excitatory and inhibitory
influences.(Ad-fibers) but most are unmyelinated (C fibers), and these
slowly conducting afferents represent the majority of sen-
sory neurons in the peripheral nervous system. Like all pri-
mary sensory neurons in the somatosensory system, they
have their cell bodies in dorsal root or trigeminal ganglia,
give rise to a single axon that bifurcates into a peripheral
branch that innervates peripheral target tissue, and a cen-
tral axon that enters the CNS to synapse on nociceptive
second order neurons. The nociceptor in consequence
has four major functional components, the peripheral ter-
minal that transduces external stimuli and initiates action
potentials, the axon that conducts action potentials, the
cell body that controls the identity and integrity of the neu-
ron, and the central terminal which forms the presynaptic
element of the first synapse in the sensory pathway in the
CNS (Figure 1). In addition to the contribution of the intrin-
sic properties of the neuron to its functional role, crucial
too are the extrinsic signals that feed onto the neuron
from targets, nerves, and the spinal cord that can produce
profound phenotypic alterations.
Loss of nociceptor neurons in patients with hereditary
sensory and autonomic neuropathy type 4, due to muta-
tions in the nerve growth factor (NGF) TrkA receptor that
result in a failure of nociceptor survival in the embryo (Ver-
poorten et al., 2006), produces congenital pain hyposensi-
tivity, and starkly reveals the importance of nociceptors as
an early warning device. These unfortunate individuals
burn and chew their tongues and lips, and as a result of
undetected damage, lose the tips of their fingers and dam-
age joints. Ignorance of noxious stimuli is not bliss. A con-
genital indifference to pain without loss of nociceptor neu-
rons has been shown recently to occur with loss of
function mutations in the SCN9A gene encoding the alpha
subunit of Nav1.7 voltage-gated sodium channel (Cox
et al., 2006; Goldberg et al., 2007).
In this review, we highlight recent insights into how no-
ciceptors differentiate from progenitors during develop-354 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.ment to achieve the specialized nociceptor molecular
phenotype, how they transduce noxious stimuli and trans-
fer input to the CNS, and how some of the adaptive and
maladaptive functional and phenotypic changes that
occur in nociceptors produce spontaneous pain and pain
hypersensitivity.
Development and Differentiation of Nociceptors
Nociceptor Genesis
Nociceptors develop from those neural crest stem cells
that migrate from the dorsal part of the neural tube and
form late during neurogenesis, whereas neurons born ear-
lier become proprioceptors or low-threshold mechano-
ceptors (Anderson, 2000; Fitzgerald, 2005; Lawson and
Biscoe, 1979; Marmigere and Ernfors, 2007). All newly
formed embryonic nociceptors express the TrkA nerve
growth factor receptor (Marmigere and Ernfors, 2007).
However, the transcription factors that determine noci-
ceptor cell fate remain unclear. Formation of most TrkA+
neurons is dependent on the proneural transcription factor
Neurogenin1 (Ngn1) (Ma et al., 1998, 1999). Ngn1 activity
is, however, not specific for nociceptors—it’s also re-
quired for formation of TrkB+ and TrkC+ low-threshold me-
chanoceptors (Ma et al., 1998, 1999). The homeobox gene
Brn3a and the zinc finger gene Klf7 are required for the
maintenance, but not the initiation of TrkA expression,
but these transcription factors are also like Ngn1, ex-
pressed in both developing nociceptors and nonnocicep-
tors (Lei et al., 2006). The Runx1 runt domain transcription
factor is however, expressed exclusively in TrkA+ neurons
at early embryonic stages (Chen et al., 2006; Kramer et al.,
2006; Levanon et al., 2002; Marmigere et al., 2006; Ther-
iault et al., 2005; Yoshikawa et al., 2007), but because its
expression is initiated some time after the onset of TrkA
expression, it is unlikely to be involved in early nociceptor
cell fate determination (Chen et al., 2006).
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(A) Progressive segregation of peptidergic ver-
sus nonpeptidergic nociceptors. Note that
Runx1 expression is extinguished in prospec-
tive TrkA+ peptidergic neurons, but the signals
that trigger Runx1 downregulation in these
neurons remain elusive (‘‘?’’).
(B) An interaction network that controls ex-
pression of nociceptor-specific molecules.
The purple arrow indicates that TrkA signaling
is required to maintain Runx1 expression at
perinatal stages, but it remains unknown if
TrkA signaling is directly involved in this pro-
cess. The signals that control the initiation of
Runx1 expression are also unknown (‘‘??’’).
The dashed arrow indicates possibility that
Runx1 has a direct role in controlling expres-
sion of TRPA1, MrgA1, A3 and B4, although
Runx1 could activate these genes by regulating
Ret.Segregation of Peptidergic versus Nonpeptidergic
Nociceptors
Following sensory neurogenesis, prospective nociceptors
undergo two distinct differentiation pathways that lead to
the formation of two major classes of nociceptors, pepti-
dergic and nonpeptidergic nociceptors. These two sets
of nociceptors express distinct repertoires of ion channels
and receptors and innervate distinct peripheral and cen-
tral targets (Braz et al., 2005; Chen et al., 2006; Snider
and McMahon, 1998; Zylka et al., 2005). During the
perinatal and postnatal period, about half of developing
nociceptors switch off TrkA and begin to express Ret,
the transmembrane signaling component of the receptor
for glial cell-derived growth factor (GDNF) and other
GDNF-related growth factors. These neurons become
the nonpeptidergic nociceptors, most of which bind iso-
lectin B4 (IB4+). The remaining nociceptors retain TrkA
(a few also coexpress Ret) and develop into the peptider-
gic class of nociceptors that express CGRP and SP and
do not bind IB4 (IB4) (Bennett et al., 1996; Molliver
et al., 1997).
The dynamic expression of Runx1 appears to be an im-
portant player in this process (Figure 2; Chen et al., 2006;
Kramer et al., 2006; Yoshikawa et al., 2007). Early embry-
onic nociceptors share a similar molecular identity, coex-
pressing both TrkA and Runx1 (Chen et al., 2006). During
the period when nociceptor segregation occurs, Runx1’s
expression is extinguished in prospective TrkA+ peptider-
gic cells but persists in nonpeptidergic neurons (Chen
et al., 2006). Conditional knockout of Runx1 in the DRG
transforms these nonpeptidergic cells to a TrkA+ CGRP+
identity, and in this situation most nociceptors develop
as peptidergic nociceptors (Chen et al., 2006; Yoshikawa
et al., 2007). Conversely, constitutive expression of Runx1
in all nociceptors is sufficient to suppress embryonic pep-
tidergic differentiation (Kramer et al., 2006). Runx1 also
coordinates afferent targeting to the spinal cord; in mice
that lack Runx1 prospective IB4+ nonpeptidergic afferents
adopt the projection pattern typical of peptidergic affer-
ents (Chen et al., 2006). These observations suggest
that persistent Runx1 expression promotes the Ret+ non-peptidergic cell fate, whereas loss of Runx1 is essential for
peptidergic differentiation.
Several recent studies suggest that Runx1 and TrkA/Ret
signaling pathways form a complex interaction loop for
establishing nonpeptidergic nociceptor cell fate (Ibanez
and Ernfors, 2007 ; Luo et al., 2007). TrkA-signaling is re-
quired to activate Ret, partly it appears by maintaining
Runx1 expression at perinatal stages (Luo et al., 2007).
Raf kinases acting downstream of TrkA or other signaling
molecules are required to maintain Ret expression by
controlling expression of the Runx1 cofactor protein,
CBF-b (Zhong et al., 2006). Finally, Ret signaling acts to
suppress TrkA expression in prospective nonpeptidergic
neurons (Luo et al., 2007; Figure 2).
However, despite progress in teasing out the determi-
nants of nociceptor specification, several issues remain
to be resolved. Because both TrkA and Ret are required
for afferents to innervate peripheral targets (Luo et al.,
2007; Patel et al., 2000), a loss of either TrkA or Ret signal-
ing prevents nociceptors from receiving other target-
derived signals. Consequently, it is not known if TrkA
signaling directly or indirectly controls expression of
Runx1, CBF-b, and Ret, or if Ret signaling is directly
involved in TrkA suppression. In addition, while TrkA sig-
naling is required to maintain Runx1 expression at embry-
onic stages, Runx1 expression is extinguished from TrkA+
peptidergic nociceptors during perinatal/postnatal devel-
opment, and we need to determine, therefore, if TrkA
signaling switches from activating to suppressing Runx1
expression at different developmental stages or if a
peripheral innervation defect in the absence of TrkA sig-
naling indirectly extinguishes Runx1 expression. A further
problem is that the intrinsic transcription factors that es-
tablish peptidergic nociceptor cell fate still remain elusive.
Although Runx1 suppresses TrkA expression during post-
natal development (Chen et al., 2006), it is capable of ac-
tivating TrkA expression after ectopic expression in the
neural tube and migratory neural crest cells (Marmigere
et al., 2006). Runx1 can, therefore, exert opposing activi-
ties depending on the cellular context. It will be extremely
interesting to establish if changes in context-dependentNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 355
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switches in nociceptors that occur in pathological condi-
tions (see below).
Regulation of Nociceptive Ion Channels
and Receptors
The mature nociceptor expresses dozens of ion channels
and receptors, and the correct establishment of their
expression is essential for nociceptors to detect spe-
cific noxious stimuli (see below, ‘‘The Differentiated Noci-
ceptor’’). There are two notable features about the devel-
opmental control of sensory channels/receptor
expression. First, many sensory channels/receptors are
expressed in only a partially overlapping or mutually ex-
clusive manner, including TRP class thermal/chemical re-
ceptors and Mrg class G protein-coupled receptors (Dong
et al., 2001; Hjerling-Leffler et al., 2007; Story et al., 2003;
Zylka et al., 2003). Second, the emergence of individual
sensory channels/receptors is subject to complex tempo-
ral control. For example, expression of three TRP chan-
nels, TRPV1, TRPM8, and TRPA1, is initiated at E12.5,
E16.5, and P0, respectively (Hjerling-Leffler et al., 2007),
while TRPA1 expression in peptidergic nociceptors is
established at P0 and nonpeptidergic nociceptors at P14,
respectively (Hjerling-Leffler et al., 2007).
The complex expression pattern of sensory channels
and receptors is established through a series of hierarchi-
cal controls. TrkA signaling is required to establish the mo-
lecular and functional identity of nociceptors (Lewin, 1996;
Luo et al., 2007; Patel et al., 2000; Ritter et al., 1991).
Runx1 is required to activate expression of a large fraction
of nociceptor-specific ion channels and receptors (Chen
et al., 2006). All known sensory receptors associated
with nonpeptidergic nociceptors are, for example, elimi-
nated in Runx1 conditional knockout mice, including the
TRP channel TRPC3, the ATP-gated P2X3 receptor, the
sodium channel Nav1.9, and a dozen Mrg-class GPCRs
(Chen et al., 2006). Transient Runx1 expression in pepti-
dergic nociceptors is also required for expression of
TRP thermal/chemical receptors, including TRPM8,
TRPA1, TRPV1, and TRPV2. Runx1, however, is dispens-
able for or even suppresses the expression of a separate
group of ion channels/receptors, including acid-sensing
ion channels (ASIC1-3), the opioid receptor MOR, and
the sodium channel Nav1.8/SNS (Chen et al., 2006). In
other words, nociceptor sensory channels/receptors can
be divided into Runx1-dependent and Runx1-indepen-
dent subgroups (Figure 2). Runx1-dependent genes are
further divided into three groups: (1) Ret-dependent, (2)
Ret-independent and TrkA-dependent, and (3) Ret-inde-
pendent and TrkA-independent (Luo et al., 2007). Runx1
is selectively required for thermal but not mechanical
pain sensitivity in vivo (Chen et al., 2006), supporting the
idea that specification of nociceptive mechanical and
thermal sensitivity is subject to separate genetic control.
In summary, intrinsic factors, such as Runx1, interface
with target-derived signals like NGF and GDNF to estab-
lish nociceptor diversity. The close interaction between
extrinsic signals and intrinsic factors must also contribute356 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.to the capacity of nociceptors to considerable plasticity in
pathological conditions (see below).
The Differentiated Nociceptor
Peripheral Terminal
The peripheral terminal of the mature nociceptor is its rai-
son d’etre. This is where noxious stimuli are detected and
transduced into inward ‘‘generator’’ currents that, if suffi-
ciently large, begin to drive action potentials along the
axon to the CNS and in this way set in train the events
that ultimately lead to a conscious awareness of the nox-
ious stimulus, pain. The sensory specificity of the nocicep-
tor is established by expression of ion channels tuned to
respond with a high threshold only to particular features
of the mechanical, thermal, and chemical environment
(Ramsey et al., 2006). The high threshold of these trans-
ducers differentiates nociceptors from sensory neurons
that respond to innocuous stimuli by virtue of expressing
tranducers with low thresholds. The identification and
characterization of nociceptor transducers over the past
decade, starting with TRPV1 by David Julius and col-
leagues (Caterina et al., 1999), has been one of the great
success stories of sensory biology and now includes
TRP, ASIC, and potassium and ligand-gated ion channels.
Initially it appeared that the function of nociceptors
would be easily defined by identifying nociceptor-specific
transducers, characterizing their properties in heterolo-
gous expression systems, and studying the phenotype
of mice with null mutations of these genes. Not too surpris-
ingly, it is rather more complicated. While TRPV1, for ex-
ample, initially looked from its threshold, which coincides
with that of heat pain (42C), as if it might be responsible
alone for this sensation (Caterina et al., 1999), thermal sen-
sitivity in the warm-hot range turns out to be mediated
by multiple TRP channels—TRPV1, TRPV2, TRPV3, and
TRPV4 (Dhaka et al., 2006)—that all express a particular
C-terminal domain that confers this sensitivity (Brauchi
et al., 2006). The extent to which all these TRPs are ex-
pressed in heat-responsive nociceptor neurons remains
uncertain. Heat-evoked activity in nociceptors may also
be modulated by coexpression of heat-sensitive potas-
sium channels like TREK-1 (Alloui et al., 2006) whose
activity is reduced by increased heat.
While all now agree that cool stimuli are sensed by
the TRPM8 channel (Bautista et al., 2007; Colburn et al.,
2007; Dhaka et al., 2007), which has a different C-terminal
domain from heat sensitive TRPs (McKemy et al., 2002),
there is some uncertainty over which channel(s), TRPM8,
TRPA1, or another channel, detect intense cold, the cold
that produces a ‘‘burning’’ pain (Bandell et al., 2004;Jordt
et al., 2004), since TRPM8 null mice still respond to intense
cold (Dhaka et al., 2007; Bautista et al., 2007). Knockouts
do not always produce identical phenotypes and therefore
do not provide direct answers but sometimes pose more
questions, as in the case of TRPA1 null mice (Bautista
et al., 2006; Kwan et al., 2006). The contribution of
TRPA1 to cold sensitivity of DRG neurons in vitro could
be indirect; cold increases [Ca2+]i, and Ca
2+ directly
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2007). Interestingly, while tactile sensibility and motor
function deteriorate in the cold, pain perception persists,
and this is achieved by expression in nociceptor periph-
eral terminals of the TTX-R Nav1.8 voltage-gated sodium
channel, whose inactivation, unlike TTX-S channels, is
cold resistant (Zimmermann et al., 2007).
There is even more uncertainty about noxious mechan-
ical transduction with several competing but unvalidated
candidates for the high-threshold ‘‘pinch’’ mechanotrans-
ducer that include TRPs, ASICs, and potassium channels
(Hu et al., 2006). A null mutation of stomatin-like protein 3
(SLP3), a mammalian mec-2 homolog expressed in sen-
sory neurons, leads to loss of mechanosensitivity in low-
threshold Ab and high threshold Ad fibers, but not in C
fiber polymodal nociceptors (Wetzel et al., 2007). While
SLP3 may be, therefore, an essential subunit of some me-
chanotransducers, possibly with ASIC channels, the iden-
tity of the C nociceptor mechanotransducer still remains
elusive. In C. elegans, mutations of trpa-1, the ortholog
of TRPA1, result in defects in mechanosensory behaviors
(Kindt et al., 2007), but the role of this channel to mecha-
nosensation in vertebrates is still uncertain.
Many TRP channels are sensitive to a gourmet collec-
tion of pungent chemicals from chili, garlic, peppermint,
mustard, horseradish, oregano, savory, clove, and thyme
(Macpherson et al., 2005; Xu et al., 2006), as well as less
pleasantly to environmental irritants such as acrolein,
a Word War I chemical weapon and component of ciga-
rette smoke (Bautista et al., 2006), and to some spider
toxins (Siemens et al., 2006). A remarkable finding is that
mustard oil and other TPA1-activating irritants produce
a direct reversible covalent modification of reactive cys-
tines in the N-terminal region of the channel to activate it
(Macpherson et al., 2007; Hinman et al., 2006). In addition
to this capacity to detect multiple extrinsic chemical sig-
nals, endogenous ligands like the endocannabinoid anan-
damide activate TRP channels (van der Stelt et al., 2005),
and this and other fatty acid amides like N-acyl-taurine
(Saghatelian et al., 2006), may enable the channels to de-
tect change in tissues independent of external stimuli.
While each transducer channel was originally thought to
identify its own ‘‘adequate’’ stimulus, heteromultimers of
TRP channels are possible (Liapi and Wood, 2005), and
the presence of these in sensory neurons and the trans-
duction properties of such complexes, if they exist, need
to be explored. Moreover, TRP splice variants may act
as endogenous TRP inhibitors, regulating sensitivity (Vos
et al., 2006; Wang et al., 2004). What is certain though,
is that there is a major coupling between GPCRs and
some TRP channels in the membrane. TRPA1, for exam-
ple, acts as a receptor-operated channel for bradykinin,
generating calcium influx in response to activation of the
B2 receptor (Bautista et al., 2006). This type of coupling
may be true for other inflammatory mediators/chemokines
both with TRPA1 and other TRP channels and provides
a means for GPCRs and receptor tyrosine kinases to de-
polarize the terminal. As a result, although the fundamen-tal role of nociceptors is to detect potentially tissue-dam-
aging stimuli, if damage has occurred this can also be
detected by release of bradykinin and other ligands whose
receptors are coupled to TRP receptors.
TRPA1 appears to be a major integrator of diverse
chemical (wasabi, mustard, raw garlic, and bradykinin)
and perhaps even of thermal and mechanical noxious
stimuli as well (Bandell et al., 2004, 2006; Kwan et al.,
2006) and possesses at the molecular level a feature char-
acteristic of many nociceptors that they are polymodal
and respond to several different kinds of input. TRPV1 is
also polymodal, detecting heat and multiple chemical
(capsaicin, proton, spider toxins) stimuli (Dhaka et al.,
2006). Nevertheless, there is also nociceptor specificity
spanning diverse ranges of thresholds and sensitivities
to exogenous and endogenous stimuli. Some nociceptors
have quite low thresholds with maximal responses in the
noxious range, not unlike the TRPV3 and TRPV4 channels;
others have thresholds so high that they do not normally
respond to noninjurious stimuli, similar to TRPV2, and
these are called sleeping nociceptors because they
‘‘wake’’ and become responsive only in the presence of
inflammation.
Peripheral Sensitization
Peripheral sensitization represents a form of stimulus-
evoked functional plasticity of the nociceptor. The stimu-
lus in this situation is a set of inflammatory mediators re-
leased from injured and inflammatory cells that sensitize
it, reducing threshold and increasing responsiveness
(Figure 3). Essentially at the site of injury/inflammation
and as a result of the change in the chemical milieu pro-
duced by disruption of cells, degranulation of mast cells,
secretion by inflammatory cells, and induction of enzymes
like cyclooxygenase-2, nociceptors change from being
exclusively noxious stimulus detectors to detectors also
of innocuous inputs. As a result, low-intensity stimuli
gain access to the nociceptive pathway and begin to pro-
duce pain. A broad range of sensitizers do this, including
kinins, amines, prostanoids, growth factors, chemokines,
and cytokines, which with protons and ATP make up an
‘‘inflammatory soup’’ that is ‘‘tasted’’ by the nociceptor
terminal and as a result changes it. Several new ingredi-
ents of the soup have been identified, including the
TGFb member activin (Xu and Hall, 2006), TNFa (Jin and
Gereau, 2006), the chemokine CCL3 (Zhang et al.,
2005a), prokineticins (Vellani et al., 2006), proteases that
activate protease-activated GPCR receptors (Grant
et al., 2007; Dai et al., 2007), and GDNF (Malin et al.,
2006). The large numbers of sensitizing agents acting in
parallel makes interruption of their effects a fairly poor op-
tion to treat inflammatory pain. Nevertheless, treatment
that blocks PGE2 synthesis consequent on local induction
of COX-2 has been the basis of most nonsteroidal anti-in-
flammatory mild analgesics. Several other approaches
targeting specific sensitizers are under development,
such as anti-NGF antibodies, but these are likely always
to have a ceiling effect, reducing but not eliminating
pain, since other sensitizers will still be available. MoreNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 357
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(A) Peripheral sensitization involves a lowering
of the threshold of the nociceptor in response
to inflammatory sensitizers that activate, via di-
verse signal transduction pathways in the pe-
ripheral terminal, alterations in the trafficking
and properties of transducer and sodium chan-
nels, largely as a result of phosphorylation.
(B) Phenotypic switches occur in nociceptors
in response to inflammation and axonal injury
by virtue of exposure to retrogradely trans-
ported signal molecules or absence of target-
derived signals.effective analgesics for local inflammatory pain may well
be ones that can act downstream of the convergence of
multiple different sensitizers on the effectors of the in-
creased excitability.
Nociceptor sensitizers produce their effects on binding
to their receptors on the nociceptor membrane by activa-
tion of multiple intracellular signal transduction pathways
in the peripheral terminal that include PKC (Hucho et al.,
2005), PKA (Varga et al., 2006), PI3K (Malik-Hall et al.,
2005), the MAP kinases ERK and p38 (Jin and Gereau,
2006; Mizushima et al., 2007), as well as JNK (Doya
et al., 2005). Downstream of these cascades, the effectors
of peripheral sensitization are mainly phosphorylation of
TRP and voltage-gated sodium channels, altering thresh-
old and kinetics (Figure 3). Endogenous PIP2 in the noci-
ceptor membrane inhibits TRPV1, leading to the sugges-
tion that activation of PLCg by TrkA by metabolizing PIP2
relieves TRPV1 from inhibition to produce sensitization
(Chuang et al., 2001). Alternatively TrkA may activate a sig-
naling pathway involving PI3 kinase early and Src kinase as
the downstream element that phosphorylates TRPV1
(Zhang et al., 2005b). Insertion of TRPV1 into the mem-
brane from intracellular stores may represent another
mode, apart from changing threshold, of increasing trans-
duction sensitivity (Zhang et al., 2005b). From multiple
knockout studies, it appears that both TRPV1 and
TRPA1 have a considerable contribution to peripheral sen-
sitization (Bautista et al., 2006; Caterina et al., 2000; Davis
et al., 2000; Kwan et al., 2006), as do the VGSCs, Nav1.8,
Nav1.7, and Nav1.9 (Amaya et al., 2006; Kerr et al., 2001;
Nassar et al., 2004, 2005, 2006). TRP receptor antagonists
and sodium channel selective blockers may be a useful ap-
proach, therefore, for reducing peripheral sensitization and
thereby inflammatory pain (Jarvis et al., 2007).
Mutations in the intracellular linker parts of the Nav1.7
voltage-gated sodium channel and in its S4 segment
increase the excitability of nociceptors and produce in-
herited erythermalgia, a condition where warm stimuli
provoke episodic burning pain (Choi et al., 2006). This358 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.channelopathy indicates the crucial contribution of so-
dium channels not only to action potential conduction,
but also to the threshold and responsiveness of nocicep-
tors. Some patients with postherpetic neuralgia develop
burning pain with a reduced thermal threshold that has
been considered to be the result of an ‘‘irritable nocicep-
tor’’ (Fields et al., 1998). Whether this reflects a herpes
zoster-induced acquired alteration in Nav1.7 distribution
due to altered trafficking or function, resulting from post-
translational changes is an intriguing possibility. Recently,
individuals homozygous for nonsense mutations in Nav1.7
that lead to a complete loss of function when expressed
heterologously have been found to have an inability to
feel pain, without any loss of innocuous sensitivity (Cox
et al., 2006; Goldberg et al., 2007). Given expression in
nociceptor neurons of several tetrodotoxin-sensitive
(Nav1.6, Nav1.7) and resistant (Nav1.8 and Nav1.9) sodium
channels, the complete loss of pain sensitivity is remark-
able. Global loss of Nav1.7 is lethal in mice, and a spatial
knockout restricted to nociceptors produces no major
change in nociception (Nassar et al., 2004), indicating
that null mutations in mice and men produce very different
phenotypes! It is possible in humans that Nav1.7 plays
a key role in producing the generator potential that
amplifies transducer-mediated depolarizations to initiate
action potentials, in the action potential itself, or in pre-
venting branch point blockade.
Phenotypic Switches
The cell bodies of nociceptor neurons in the dorsal root
ganglion need to keep themselves informed about the sta-
tus of their peripheral terminals. Peripheral inflammation,
in addition to driving peripheral sensitization, produces
retrograde signals in nociceptor neurons that increase in
the soma the transcription of neuropeptides, BDNF, and
sodium channels, as well as increasing the translation of
TRP channels to augment both central transmission and
peripheral sensitization (Ji et al., 2002; Mannion et al.,
1999; Neumann et al., 1996; Figure 3). Furthermore, in-
flammation via NGF increases expression of mu-opiod
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2004). Transport of NGF-activated Trk receptors and per-
haps those of other growth factors from the periphery ap-
pear to be a major means whereby nociceptor cell bodies
change in response to peripheral inflammation (Delcroix
et al., 2003). In general terms, inflammation tends to cause
an expansion or increase in the expression of specific no-
ciceptive ion channels/receptors. The increase in expres-
sion, while functionally significant, is quite limited in
scope, and the underlying transcriptional mechanisms
are unclear and may involve axonal transport of tran-
scripts and local translation.
If the peripheral axon of nociceptors is severed, disrupt-
ing contact of the cell body with its terminal and in this way
with the peripheral target, profound changes in transcrip-
tion occur. Negative signals such as a loss of target-
derived growth factors and positive signals like retrograde
protein kinase G (Sung et al., 2006) or a vimentin-
dependent translocation of activated ERK (Perlson et al.,
2006) drive activation of multiple signal-transduction path-
ways in the cell body that alter transcription in >1000
genes (Costigan et al., 2002;Xiao et al., 2002). Some of
these represent attempts by the neuron to survive the ma-
jor physical and metabolic insult inherent in the injury,
others are attempts for the axon to regrow, but many ax-
otomy-induced transcriptional changes are maladaptive
and produce alterations in function that can drive neuro-
pathic pain. Injured neurons lose some normal nociceptor
features with, for example, a downregulation of TRP and
sodium channels, while at the same time gaining a new
molecular identity. One example of this is the upregulation
in DRG neurons of enzymes involved in the synthesis and
recycling of tetrahydrobiopterin (BH4) after peripheral ax-
onal injury (Tegeder et al., 2006). BH4 is an essential co-
factor for aromatic amine hydroxylases and nitric oxide
synthases, and its increase drives NO production in
DRG neurons, which in turn increases calcium influx in
the neurons. Inhibition of BH4 synthesis produces analge-
sia, while BH4 produces pain-like behavior. Intriguingly,
a human variant of the rate-limiting enzyme in the BH4
pathway, GTP cyclohydrolase, which produces less BH4
in response to stressors, is associated with less chronic
pain in patients after surgery (Tegeder et al., 2006). Al-
though injured DRG neurons show a major phenotypic
shift, so do their spared noninjured neighbors, and indeed
it is these cells that may drive much spontaneous pain.
Spontaneous Activity and Pain
Peripheral sensitization produces a state of heightened
sensitivity to peripheral stimuli that are either normally
innocuous or are noxious but now produce exaggerated
or prolonged effects both represent stimulus-dependent
pains. A common aspect of clinical pain conditions,
however, is pain in the absence of any readily identifi-
able stimulus, stimulus-independent pain. Spontaneous
pain may arise from signal molecules continuously re-
leased after tissue damage or inflammation that act on
nociceptor peripheral terminals to either drive a depolar-
ization sufficient to initiate action potentials or producea reduction in threshold such that normal ambient tem-
peratures or the pulsation of blood vessels now activate
what had been high-threshold thermo- and mechano-
nociceptors. After peripheral inflammation and periph-
eral nerve lesions, spontaneous foot lifting, a surrogate
of spontaneous pain, correlates with spontaneous activ-
ity in C fibers but not with allodynia, implying that spon-
taneous pain is driven from the periphery and differs
mechanistically from stimulus-evoked pain (Djouhri
et al., 2006).
The nociceptor is designed to initiate activity only at its
peripheral terminal. Any action potentials that originate
from the axon or cell body represent pathological ectopic
firing and produce sensory inflow in the absence of sen-
sory stimuli or ongoing peripheral inflammation. Ectopic
activity can be generated by pacemaker-like spontaneous
depolarizations resulting from an abnormal hyperexcit-
ability of the membrane that occurs after peripheral nerve
injury due to alterations in ion channel expression and traf-
ficking (Liu et al., 2002). Although injured DRG neurons
display ectopic activity, increasingly it is recognized that
neighboring intact fibers are, after partial peripheral nerve
injury, an even larger source of such spontaneous activity
(Djouhri et al., 2006). One explanation for this is that the in-
tact fibers are exposed to signal molecules produced by
deafferented Schwann cells, such as TNFa. Several chan-
nels may contribute to ectopic action potential initiation in-
cluding a hyperpolarization-activated, cation-nonselec-
tive, cyclic nucleotide-modulated channel (Lee et al.,
2005), a Ca-activated chloride current (Hilaire et al.,
2005), as well as potassium and sodium channels. Sodium
channels seem obvious candidates both because of their
intrinsic properties and because sodium channel blockers
produce analgesia in some patients with neuropathic pain.
However, while antisense knockdown has implicated
Nav1.8 in rodent models of neuropathic pain (Gold et al.,
2003), surprisingly knockouts of Nav1.8, 1.9, 1.7 and 1.3
have no change in the neuropathic pain phenotype (Amaya
et al., 2006; Nassar et al., 2004, 2005, 2006; Priest et al.,
2005). Selective sodium channel blockers will be required
to resolve whether these channels are the major drivers of
spontaneous activity after nerve injury and represent the
best target for treating the severe lancinating or shock-
like pain these patients experience (Jarvis et al., 2007).
Presynaptic Terminal
The central terminals of nociceptors are located in the su-
perficial dorsal horn of the spinal cord for somatic neurons
and in the spinal nucleus of the trigeminal for those inner-
vating the face (Figure 1). These terminals drive synaptic
input to second-order neurons, transferring information
carried by action potentials about the intensity and dura-
tion of peripheral noxious stimuli. The rostrocadual and
mediolateral topography of the central terminal reflects
the spatial location of the peripheral terminal, while their
dorsoventral location reflects the identity of the nociceptor
as a result of the coordination between specification and
axonal guidance during development. Unlike low-thresh-
old primary sensory neurons that use glutamate as theirNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 359
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Reviewsole transmitter, nociceptors variously use glutamate,
neuropeptides, and proteins like BDNF as transmitters/
synaptic modulators and in consequence evoke fast and
slow excitatory postsynaptic potentials that show consid-
erable spatial and temporal summation.
Transmitter release is regulated by multiple factors that
control or modulate calcium influx in response to the inva-
sion of the terminal by action potentials to activate the
vesicle-release machinery. The major voltage-gated cal-
cium channel in nociceptors is Cav2.2, and alternative
splicing of the mRNA of the channel results in a structurally
and functionally distinct N-type calcium channel splice
isoform in subsets of nociceptors (Castiglioni et al.,
2006). The alternative spliced variant of Cav2.2 uniquely
is sensitive to a G protein-coupled receptor voltage-
dependent and voltage-independent inhibition (Raingo
et al., 2007). The N-type channel blocker ziconatide, a con-
otoxin, produces analgesia, but its side-effect profile
necessitates intrathecal delivery; use-dependent Cav2.2
blockers may have a greater therapeutic index, as may
those that have greater selectivity for the nociceptor-spe-
cific splice isoform. In addition to the pore-forming a sub-
unit, calcium channels have accessory subunits including
the a2d subunit, which is the binding site for gabapentin
and pregabalin, drugs with efficacy in neuropathic pain
(Field et al., 2006). It is not clear though, exactly how these
drugs act to produce analgesia; they are not calcium-
channel blockers, but there are suggestions that they
may under some circumstances reduce transmitter re-
lease. The a2d subunit is upregulated in nociceptor ter-
minals after peripheral axonal injury and represents an
example of a target induced in particular disease condi-
tions. Part of pain therapy needs to be, therefore, the
matching of drugs for those situations that their targets
are present and contributing to the pain.
Transmitter-modulated reductions in transmitter re-
lease from nociceptors is a prominent control mechanism
in nociception, increasing or decreasing access of no-
ciceptor input to the CNS, and includes endogenous
opioids acting on mu- and delta-opiate receptors, GABA
on GABAB receptors, and endogenous cannabinoids on
CB1 receptors, a regular den of receptors for drugs of
abuse (Figure 1). The level of these receptors changes
dynamically with in the case of the mu-opiate receptor,
an increase after inflammation (Puehler et al., 2004) and
a decrease after axonal injury (Kohno et al., 2005). The
delta-opiate receptor (DOR) has another form of regula-
tion. Very little of the receptor is normally inserted in the
nociceptor terminal membrane; most is located in the
membrane of peptide-containing, large dense core vesi-
cles. Following nociceptor activation, fusion of the vesi-
cles to the terminal membrane during synaptic release
due to stimulus-triggered exocytosis introduces the
receptor to the terminal in a manner that depends on an
interaction between DOR and preprotachykinin (Guan
et al., 2005). DOR-mediated analgesia requires then prior
activation of the nociceptor—pain before analgesia. Sur-
prisingly, deletion of CB1 only in nociceptors has revealed360 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.that cannabinoids exert their analgesic action primarily on
CB1 receptors expressed on the peripheral terminals of
nociceptors (Agarwal et al., 2007), which may enable de-
velopment of peripherally acting cannabinoid analgesics
without central side effects.
Balanced against the braking influences on the central
terminal are those that act to increase transmitter release,
including PGE2 (Vasko, 1995) and bradykinin (Wang et al.,
2005). In this respect, the central terminal of the nocicep-
tor resembles its peripheral terminal. PGE2 is produced
following induction of COX-2 in dorsal horn neurons in re-
sponse to peripheral inflammation (Samad et al., 2001),
while bradykinin is released in the spinal cord in within
minutes of nociceptor input (Wang et al., 2005), and
both act via their G protein-coupled receptors to increase
transmitter release. Bradykinin increases calcium influx
via the TRPA1 channel (Bautista et al., 2006), which may
act therefore as a regulator of transmitter release (Kosugi
et al., 2007). It turns out that a major component of the an-
algesic action of TRPV1 antagonists is surprisingly on the
central and not on the peripheral terminal of nociceptors
(Cui et al., 2006). This raises the question as to what li-
gands or stimuli drive the receptor here. It is obviously
not heat, and fatty acid amides are likely endogenous li-
gand candidates. In addition to regulating the flow of infor-
mation by transmitter release, nociceptor neurons also
produce chemokine signals after axonal injury that acti-
vate microglia in the dorsal horn to contribute to alter-
ations in sensory processing in the spinal cord (Verge
et al., 2004).
Conclusion
The nociceptor neuron is highly specialized to respond
only to noxious stimuli and communicate this information
accurately to the CNS. It is however, not a static detector;
the functional and chemical plasticity of the receptor en-
sures that its threshold and responsiveness, as well as
the efficacy of its synaptic contacts, are regulated to re-
flect changes produced by activity, inflammation, and ax-
onal injury. Heightened pain sensitivity can contribute to
healing by helping avoid contact with the damaged body
part until repair has occurred. Persistent alterations in no-
ciceptors that drive pain in the absence of noxious stimuli
or inflamed or damaged tissue represent, by contrast,
a pathological change in the nociceptive system, and suc-
cessful treatment of such pain requires restoring the noci-
ceptor to its normal function—silent except in the pres-
ence of imminent danger. This requires understanding
its normal function and how it changes, particularly in re-
sponse to axonal injury, something that we have made
considerable progress in achieving since Sherrington first
recognized the existence of these sensory neurons a
century ago.
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